Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
1 November 1994 | Volume 121 Issue 9 | Pages 633-640
Objective: To determine the following: a reference range for serum calcitriol during hypercalcemia in a control group of patients with myeloma in whom calcitriol production is known to be appropriately suppressed; the incidence of elevated serum calcitriol levels in hypercalcemic patients with non-Hodgkin lymphoma according to this derived reference range; and the incidence of abnormal calcium metabolism in normocalcemic patients with non-Hodgkin lymphoma.
Design: Prospective clinical study.
Setting: Referral cancer center.
Patients: 2 groups of hypercalcemic patients: 16 control patients with myeloma and 22 patients with non-Hodgkin lymphoma divided into those with elevated or normal serum calcitriol levels; 1 group of 22 normocalcemic patients with non-Hodgkin lymphoma.
Measurements: Serum chemistries and intact parathyroid hormone, calcitriol, parathyroid hormone-related protein, and urinary electrolyte levels.
Results: On the basis of the mean serum calcitriol level of the control group plus 3 standard deviations, the reference range for serum calcitriol during hypercalcemia was defined as less than 42 pg/mL. Although serum calcium and parathyroid hormone levels in the study patients were similar to those in controls, 12 of the 22 hypercalcemic patients with non-Hodgkin lymphoma (55%) had serum calcitriol levels greater than 42 pg/mL (range, 51 to 170 pg/mL). No features distinguished the patients with elevated serum calcitriol levels from those with normal levels. Seventy-one percent of normocalcemic patients with non-Hodgkin lymphoma were hypercalciuric, and 18% had serum calcitriol levels greater than the normocalcemic reference range (20 to 76 pg/mL).
Conclusions: Serum calcitriol levels are elevated in most hypercalcemic patients with non-Hodgkin lymphoma in the absence of elevated serum levels of parathyroid hormone, which implicates extrarenal calcitriol production in the pathogenesis of this syndrome. Abnormal calcium metabolism, hypercalciuria, and dysregulated calcitriol production are also common in normocalcemic patients with non-Hodgkin lymphoma.
Author and Article Information
From the Royal Melbourne Hospital, Victoria, Australia, and the M.D. Anderson Cancer Center, Houston, Texas.
ARTICLE
Calcitriol Production in Hypercalcemic and Normocalcemic Patients with Non-Hodgkin Lymphoma
![]()
Requests for Reprints: John F. Seymour, MBBS, Department of Clinical Haematology and Medical Oncology, Royal Melbourne Hospital, Grattan Street, Parkville 3050, Victoria, Australia.
Related articles in Annals:
This article has been cited by other articles:
![]() |
G A Clines and T A Guise Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone Endocr. Relat. Cancer, September 1, 2005; 12(3): 549 - 583. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Stewart Hypercalcemia Associated with Cancer N. Engl. J. Med., January 27, 2005; 352(4): 373 - 379. [Full Text] [PDF] |
||||
![]() |
K. N. Evans, H. Taylor, D. Zehnder, M. D. Kilby, J. N. Bulmer, F. Shah, J. S. Adams, and M. Hewison Increased Expression of 25-Hydroxyvitamin D-1{alpha}-Hydroxylase in Dysgerminomas: A Novel Form of Humoral Hypercalcemia of Malignancy Am. J. Pathol., September 1, 2004; 165(3): 807 - 813. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. J. Freeman and D. Holik Uncommon Syndromes and Treatment Manifestations of Malignancy: Case 3. Richter's Syndrome Heralded by Refractory Hypercalcemia J. Clin. Oncol., January 1, 2003; 21(1): 170 - 172. [Full Text] [PDF] |
||||
![]() |
J. K. Erban and Z. Tang Case 38-2002 - A 54-Year-Old Man with Hypercalcemia, Renal Dysfunction, and an Enlarged Liver N. Engl. J. Med., December 12, 2002; 347(24): 1952 - 1960. [Full Text] [PDF] |
||||
![]() |
J. S. Adams and V. Kantorovich Inability of Short-Term, Low-Dose Hydroxychloroquine to Resolve Vitamin D-Mediated Hypercalcemia in Patients with B-Cell Lymphoma J. Clin. Endocrinol. Metab., February 1, 1999; 84(2): 799 - 801. [Abstract] [Full Text] |
||||
![]() |
T. A. Guise and G. R. Mundy Cancer and Bone Endocr. Rev., February 1, 1998; 19(1): 18 - 54. [Abstract] [Full Text] |
||||